What is claimed is:

1. Use of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) in the manufacture of a medicament for treating pemphigus in a human patient in need thereof, wherein a dose of at least 400 mg of PRN1008 is to be administered once a day (QD) for at least 14 days.

2. The use of claim 1, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient QD for 14 to 168 days.

3. The use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient QD for 14 days.

4. The use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient QD for 28 days.

5. The use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient QD for 84 days.

6. The use of claim 1 or 2, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient QD for 168 days.

7. The use of claim 1, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient QD for at least 14 days.

8. The use of claim 1 or 7, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient QD for 14 to 168 days.

9. The use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient QD for 14 days.

10. The use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient QD for 28 days.

11. The use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient QD for 84 days.

12. The use of any of claims 1, 7, or 8, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient QD for 168 days.

13. The use of claim 1, wherein:

a first dose of 400 mg of PRN1008 is to be administered to the human patient QD for 14 days; and

a second dose of 400 mg of PRN1008 is to be administered to the human patient twice a day (BID) for at least 14 days following the administration of the first dose.

14. The use of claim 13, wherein a second dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 154 days following the administration of the first dose.

15. The use of claim 1, wherein:

a first dose of 400 mg of PRN1008 is to be administered to the human patient QD for 14 days; and

a second dose of 400 mg of PRN1008 is to be administered to the human patient twice a day (BID) for 14 days following the administration of the first dose; and

a third dose of 600 mg of PRN1008 is to be administered to the human patient BID following the administration of the second dose.

16. The use of claim 15, wherein a third dose of 600 mg of PRN1008 BID is to be administered to the human patient for at most 140 days following the administration of the second dose.

17. The use of claim 15, wherein a third dose of 600 mg of PRN1008 is to be administered to the human patient BID for 56 days following the administration of the second dose.

18. Use of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) in the manufacture of a medicament for treating pemphigus in a human patient in need thereof, wherein a dose of at least 400 mg of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (PRN1008) is to be administered twice a day (BID) for at least 14 days.

19. The use of claim 18, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 84 days.

20. The use of claim 18 or 19, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 14 days.

21. The use of claim 18 or 19, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 28 days.

22. The use of claim 18 or 19, wherein a dose of at least 400 mg of PRN1008 is to be administered to the human patient BID for 84 days.

23. The use of claim 18, wherein a dose of 400 mg of PRN1008 is to be administered to be human patient BID for at least 14 days.

24. The use of claim 18 or 23, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 84 days.

25. The use of any of claims 18, 23, or 24, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 days.

26. The use of any of claims 18, 23, or 24, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 28 days.

27. The use of any of claims 18, 23, or 24, wherein a dose of 400 mg of PRN1008 is to be administered to the human patient BID for 84 days.

28. The use of claim 18, wherein:

a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for at least 14 days; and

a second dose of 500 mg of PRN1008 is to be administered to the human patient BID following the administration of the first dose.

29. The use of claim 28, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days.

30. The use of claim 28, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for more than 28 days.

31. The use of claim 28, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 33 days.

32. The use of any of claims 28-31, wherein PRN1008 is to be administered to the human patient for at most 84 days.

33. The use of claim 18, wherein:

a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for at least 14 days; and

a second dose of 600 mg of PRN1008 is to be administered to the human patient BID following the administration of the first dose.

34. The use of claim 33, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days.

35. The use of claim 33 or 34, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 22 days.

36. The use of claim 33, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for more than 28 days.

37. The use of claim 33 or 36, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 56 days.

38. The use of any of claims 33-37, wherein PRN1008 is to be administered to the human patient for at most 84 days.

39. The use of claim 18, wherein:

a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for at least 14 days;

a second dose of 500 mg of PRN1008 is to be administered to the human patient BID for at least 14 days following the administration of the first dose; and

a third dose of 600 mg of PRN1008 is to be administered to the human patient BID following the administration of the second dose.

40. The use of claim 39, wherein a first dose of 400 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days.

41. The use of claim 39 or 40, wherein a second dose of 500 mg of PRN1008 is to be administered to the human patient BID for 14 to 28 days following the administration of the first dose.

42. The use of any of claims 39-41, wherein PRN1008 is to be administered to the human patient for at most 84 days.

43. The use of any of claims 1-42, wherein PRN1008 is to be administered in combination with a first corticosteroid at a dose of less than or equal to 0.5 mg/kg/day.

44. The use of claim 43, wherein the first corticosteroid is chosen from prednisone, prednisolone, and methylprednisolone.

45. The use of any of claims 1-44, wherein the human patient is characterized by naïve or relapsing pemphigus prior to the administration of PRN1008.

46. The use of any of claims 1-45, wherein the human patient is characterized by naïve or relapsing pemphigus vulgaris prior to the administration of PRN1008.

47. The use of any of claims 1-46, wherein the human patient is characterized by naïve or relapsing pemphigus foliaceus prior to the administration of PRN1008.

48. The use of any of claims 1-47, wherein the human patient is characterized by a pemphigus disease activity index (PDAI) skin score from 8 points to 60 points prior to the administration of PRN1008.

49. The use of any of claims 1-48, wherein the human patient is characterized by a maintenance dose of less than or equal to 0.5 mg/kg/day of a second corticosteroid prior to the administration of PRN1008.

50. The use of claim 49, wherein the second corticosteroid is chosen from prednisone, prednisolone, and methylprednisolone.

51. The use of claim 49 or 50, wherein the first corticosteroid is the same as the second corticosteroid.

52. The use of claim 49 or 50, wherein the first corticosteroid is not the same as the second corticosteroid.

53. The use of any of claims 1-52, wherein PRN1008 comprises the (E) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

54. The use of any of claims 1-52, wherein PRN1008 comprises the (Z) isomer of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

55. The use of any of claims 1-52, wherein PRN1008 comprises a mixture of (E) and (Z) isomers of (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile.

56. The use of any of claims 1-55, wherein the medicament is for treating pemphigus vulgaris.

57. The use of any of claims 1-55, wherein the medicament is for treating pemphigus foliaceus.

58. The use of any of claims 1-57, wherein the medicament is for reducing average daily corticosteroid usage by the human patient.

59. The use of claim 58, wherein the medicament is for reducing average daily corticosteroid usage by the human patient by at least 20%.

60. The use of claim 58, wherein the medicament is for reducing average daily corticosteroid usage by the human patient by at least 50%.

61. The use of any of claims 1-60, wherein the medicament is for healing established pemphigus lesions.

62. The use of claim 61, wherein the medicament is for healing at least 50% of established pemphigus lesions.

63. The use of any of claims 1-62, wherein the medicament is for preventing new pemphigus lesion formation.

64. The use of any of claims 1-63, wherein the medicament is for reducing a pemphigus disease activity index (PDAI) skin score.

65. The use of claim 64, wherein the medicament is for reducing a PDAI skin score by at least 20%.

66. The use of any of claims 1-64, wherein the human patient is characterized by a pemphigus disease activity index (PDAI) skin score of 0 or 1 following the administration of PRN1008.

67. The use of claim 66, wherein the human patient is characterized by a PDAI skin score of 0 following the administration of PRN1008.

68. The use of claim 66, wherein the human patient is characterized by a PDAI skin score of 1 following the administration of PRN1008.

69. The use of any of claims 1-60, wherein the medicament is for achieving a control of disease activity of pemphigus.

70. The use of any of claims 1-60, wherein the medicament is for achieving an end of consolidation phase of pemphigus.

71. The use of claim 70, wherein more than 60% of established pemphigus lesions have healed.

72. The use of any of claims 1-60, wherein the medicament is for achieving complete remission.

73. The use of any of claims 1-72, wherein PRN1008 is to be orally administered to the human patient.

74. The use of any of claims 1-73, wherein PRN1008 is to be administered to the human patient in the form of at least one tablet.

75. The use of claim 74, wherein PRN1008 is to be administered with a glass of water.

76. The use of any of claims 1-75, wherein PRN1008 is to be administered with food.

77. The use of any of claims 1-75, wherein PRN1008 is to be administered without food.